Skip to main content

Table 1 Patient and tumor characteristics

From: Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

  N (%)
Age at operation (years)a 62 (32–91)
Tumor size (mm)a 17.5 (5–100)
Nodal status
N0 124 (70.1)
N1–3 53 (29.9)
TNM-stage
I 85 (48.0)
II 80 (45.2)
III 12 (6.8)
Estrogen receptor status
Negative 26 (14.7)
Positive 151 (85.3)
Progesterone receptor status
Negative 47 (26.6)
Positive 130 (73.4)
Her2/Neu status (FISH)
Negative 154 (87.0)
Positive 23 (13.0)
Ki-67 (%)b 18 (1-95)
Low-proliferative 94 (53.1)
High-proliferative 82 (46.3)
Nottingham histological grade
I 38 (21.5)
II 84 (47.5)
III 55 (31.1)
Molecular subtype
Luminal A 88 (49.7)
Luminal B 46 (26.0)
Luminal B Her2/Neu-overexpressing 17 (9.6)
Non-luminal Her2/Neu-overexpressing 6 (3.4)
Basal-like 20 (11.3)
Lymphovascular invasion (LVI)
Yes 24 (13.6)
No 133 (75.1)
Adjuvant radiotherapy
Breast or chest wall only 110 (62.2)
Locoregional 33 (18.6)
Adjuvant chemotherapy
Anthracyclines 53 (29.9)
Taxane-based 30 (16.9)
Other 1 (0.0)
Adjuvant endocrine therapy 151 (85.3)
Anti-Her2/Neu therapy (trastuzumab) 19 (10.7)
  1. Figures are N and (%) unless otherwise stated
  2. aMedian (range)
  3. bThe cut-off value being 20 %